, /PRNewswire/ -- Kessler Topaz Meltzer &amp; Check, LLP（www.ktmc.com）律师事务所通知投资者，针对 DexCom, Inc.（&#34;DexCom&#34;）（NASDAQ: DXCM）已提起证券集体诉讼，代表在 2024 年 1 月 8 日至 2025 年 9 月 17 日之间购买或以其他方式获得 DexCom 证券的投资者（&#34;集体诉讼期间&#34;）。主要原告的截止日期为 2025 年 12 月 26 日。
联系 KESSLER TOPAZ MELTZER &amp; CHECK, LLP： 如果您遭受了 DexCom 的损失， 您可以 点击这里 或将以下链接复制并粘贴到您的浏览器中： https://www.ktmc.com/new-cases/dexcom-inc-1?utm_source=PR_Newswire&amp;mktm=PR
您也可以通过拨打 (484) 270-1453 或发送电子邮件至 [email protected] 联系律师 Jonathan Naji, Esq.。
被告的指控不当行为： 投诉称，在集体诉讼期间，被告做出了虚假和/或误导性的陈述，和/或未能披露以下内容：（1）DexCom 对其 G6 和 G7 连续血糖监测系统进行了未经 FDA 授权的重大设计更改；（2）上述设计更改使 G6 和 G7 的可靠性低于其之前的版本，给依赖这些设备进行准确血糖读数的用户带来了重大健康风险；（3）DexCom 对 G7 的所谓增强以及该设备的可靠性、准确性和功能性进行了夸大；（4）DexCom 淡化了被污染的 G7 设备所带来的问题和健康风险的真实范围和严重性；（5）上述所有情况使 DexCom 面临更高的监管审查和执法行动的风险，以及显著的法律、声誉和财务损害；（6）因此，被告的公开声明在所有相关时间都是实质上虚假和/或误导性的。
请点击这里查看我们的视频或将此链接复制并粘贴到您的浏览器中： https://youtube.com/shorts/ToTm4-K0ODs?feature=share
主要原告流程： DexCom 投资者可以在 2025 年 12 月 26 日之前 通过 Kessler Topaz Meltzer &amp; Check, LLP 或其他律师寻求被任命为集体的主要原告代表，或者选择不采取任何行动，保持缺席集体成员。主要原告是代表所有集体成员指导诉讼的代表方。主要原告通常是具有最大财务利益的投资者或小组投资者，并且也符合拟议投资者集体的典型特征。主要原告选择律师代表主要原告和集体，如果法院批准，这些律师将成为主要或集体律师。您是否选择担任主要原告不会影响您分享任何赔偿的能力。
Kessler Topaz Meltzer &amp; Check, LLP 鼓励遭受重大损失的 DexCom 投资者直接联系该事务所以获取更多信息。
点击这里 注册此案件 或访问： https://www.ktmc.com/new-cases/dexcom-inc-1?utm_source=PR_Newswire&amp;mktm=PR
关于 KESSLER TOPAZ MELTZER &amp; CHECK, LLP： Kessler Topaz Meltzer &amp; Check, LLP（KTMC）是一家领先的美国原告方律师事务所，专注于证券欺诈集体诉讼和全球投资者保护。该事务所代表个人投资者以及机构，如主要养老金基金、资产管理公司和国际投资者。KTMC 在证券诉讼中领导了一些最大的赔偿，并获得同行和法律媒体的众多荣誉，包括《国家法律杂志》的原告热名单和原告法律的开拓者、BTI 咨询集团的最受害怕律师事务所荣誉榜、《法律智者》的年度集体诉讼律师事务所、《Lawdragon》的领先原告金融律师，以及《Law360》的原告律师行业巨头。该事务所在宾夕法尼亚州和加利福尼亚州设有办事处，业务遍及全球。有关 Kessler Topaz Meltzer &amp; Check, LLP 的更多信息，请访问 www.ktmc.com。
联系方式： Kessler Topaz Meltzer &amp; Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]
在某些司法管辖区可能被视为律师广告。过去的结果并不保证未来的结果。
来源 Kessler Topaz Meltzer &amp; Check, LLP
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE0Jk5ld3NJdGVtSWQ9REM0Mzk1MiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTQxMTI0UFJfTkVXU19VU1BSX19fX19EQzQzOTUy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE0Jk5ld3NJdGVtSWQ9REM0Mzk1MiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTQxMTI0UFJfTkVXU19VU1BSX19fX19EQzQzOTUy"/>

德康医疗

Kessler Topaz Meltzer & Check, LLP 已对 DexCom, Inc. 提起证券集体诉讼，指控其涉嫌证券欺诈。该诉讼涵盖在 2024 年 1 月 8 日至 2025 年 9 月 17 日期间购买 DexCom 证券的投资者。指控包括对葡萄糖监测系统的未经授权的设计变更、误导性陈述以及增加的监管审查。主要原告的截止日期为 2025 年 12 月 26 日。遭受损失的投资者被鼓励联系该律师事务所以获取更多信息

, /PRNewswire/ -- The law firm of Kessler Topaz Meltzer &amp; Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against DexCom, Inc. (&#34;DexCom&#34;) (NASDAQ: DXCM) on behalf of those who purchased or otherwise acquired DexCom securities between January 8, 2024, and September 17, 2025, inclusive (the &#34;Class Period&#34;). The lead plaintiff deadline is December 26, 2025.
<div class="lb-trans">, /PRNewswire/ -- Kessler Topaz Meltzer &amp; Check, LLP（www.ktmc.com）律师事务所通知投资者，针对 DexCom, Inc.（&#34;DexCom&#34;）（NASDAQ: DXCM）已提起证券集体诉讼，代表在 2024 年 1 月 8 日至 2025 年 9 月 17 日之间购买或以其他方式获得 DexCom 证券的投资者（&#34;集体诉讼期间&#34;）。主要原告的截止日期为 2025 年 12 月 26 日。
</div>CONTACT KESSLER TOPAZ MELTZER &amp; CHECK, LLP: If you suffered DexCom losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/dexcom-inc-1?utm_source=PR_Newswire&amp;mktm=PR
<div class="lb-trans">联系 KESSLER TOPAZ MELTZER &amp; CHECK, LLP： 如果您遭受了 DexCom 的损失， 您可以 点击这里 或将以下链接复制并粘贴到您的浏览器中： https://www.ktmc.com/new-cases/dexcom-inc-1?utm_source=PR_Newswire&amp;mktm=PR
</div>You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].
<div class="lb-trans">您也可以通过拨打 (484) 270-1453 或发送电子邮件至 [email protected] 联系律师 Jonathan Naji, Esq.。
</div>DEFENDANTS' ALLEGED MISCONDUCT: The complaints allege that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to its G6 and G7 continuous glucose monitoring systems that were unauthorized by the FDA; (2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (3) DexCom's purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (4) DexCom downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (5) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (6) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
<div class="lb-trans">被告的指控不当行为： 投诉称，在集体诉讼期间，被告做出了虚假和/或误导性的陈述，和/或未能披露以下内容：（1）DexCom 对其 G6 和 G7 连续血糖监测系统进行了未经 FDA 授权的重大设计更改；（2）上述设计更改使 G6 和 G7 的可靠性低于其之前的版本，给依赖这些设备进行准确血糖读数的用户带来了重大健康风险；（3）DexCom 对 G7 的所谓增强以及该设备的可靠性、准确性和功能性进行了夸大；（4）DexCom 淡化了被污染的 G7 设备所带来的问题和健康风险的真实范围和严重性；（5）上述所有情况使 DexCom 面临更高的监管审查和执法行动的风险，以及显著的法律、声誉和财务损害；（6）因此，被告的公开声明在所有相关时间都是实质上虚假和/或误导性的。
</div>Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtube.com/shorts/ToTm4-K0ODs?feature=share
<div class="lb-trans">请点击这里查看我们的视频或将此链接复制并粘贴到您的浏览器中： https://youtube.com/shorts/ToTm4-K0ODs?feature=share
</div>THE LEAD PLAINTIFF PROCESS: DexCom investors may, no later than December 26, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer &amp; Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
<div class="lb-trans">主要原告流程： DexCom 投资者可以在 2025 年 12 月 26 日之前 通过 Kessler Topaz Meltzer &amp; Check, LLP 或其他律师寻求被任命为集体的主要原告代表，或者选择不采取任何行动，保持缺席集体成员。主要原告是代表所有集体成员指导诉讼的代表方。主要原告通常是具有最大财务利益的投资者或小组投资者，并且也符合拟议投资者集体的典型特征。主要原告选择律师代表主要原告和集体，如果法院批准，这些律师将成为主要或集体律师。您是否选择担任主要原告不会影响您分享任何赔偿的能力。
</div>Kessler Topaz Meltzer &amp; Check, LLP encourages DexCom investors who have suffered significant losses to contact the firm directly to acquire more information.
<div class="lb-trans">Kessler Topaz Meltzer &amp; Check, LLP 鼓励遭受重大损失的 DexCom 投资者直接联系该事务所以获取更多信息。
</div>CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/dexcom-inc-1?utm_source=PR_Newswire&amp;mktm=PR
<div class="lb-trans">点击这里 注册此案件 或访问： https://www.ktmc.com/new-cases/dexcom-inc-1?utm_source=PR_Newswire&amp;mktm=PR
</div>ABOUT KESSLER TOPAZ MELTZER &amp; CHECK, LLP: Kessler Topaz Meltzer &amp; Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. For more information about Kessler Topaz Meltzer &amp; Check, LLP, please visit www.ktmc.com.
<div class="lb-trans">关于 KESSLER TOPAZ MELTZER &amp; CHECK, LLP： Kessler Topaz Meltzer &amp; Check, LLP（KTMC）是一家领先的美国原告方律师事务所，专注于证券欺诈集体诉讼和全球投资者保护。该事务所代表个人投资者以及机构，如主要养老金基金、资产管理公司和国际投资者。KTMC 在证券诉讼中领导了一些最大的赔偿，并获得同行和法律媒体的众多荣誉，包括《国家法律杂志》的原告热名单和原告法律的开拓者、BTI 咨询集团的最受害怕律师事务所荣誉榜、《法律智者》的年度集体诉讼律师事务所、《Lawdragon》的领先原告金融律师，以及《Law360》的原告律师行业巨头。该事务所在宾夕法尼亚州和加利福尼亚州设有办事处，业务遍及全球。有关 Kessler Topaz Meltzer &amp; Check, LLP 的更多信息，请访问 www.ktmc.com。
</div>CONTACT: Kessler Topaz Meltzer &amp; Check, LLP
<div class="lb-trans">联系方式： Kessler Topaz Meltzer &amp; Check, LLP
</div>Jonathan Naji, Esq.
<div class="lb-trans">Jonathan Naji, Esq.
</div>(484) 270-1453
<div class="lb-trans">(484) 270-1453
</div>280 King of Prussia Road
<div class="lb-trans">280 King of Prussia Road
</div>Radnor, PA 19087
<div class="lb-trans">Radnor, PA 19087
</div>[email protected]
<div class="lb-trans">[email protected]
</div>May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
<div class="lb-trans">在某些司法管辖区可能被视为律师广告。过去的结果并不保证未来的结果。
</div>SOURCE Kessler Topaz Meltzer &amp; Check, LLP
<div class="lb-trans">来源 Kessler Topaz Meltzer &amp; Check, LLP
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE0Jk5ld3NJdGVtSWQ9REM0Mzk1MiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTQxMTI0UFJfTkVXU19VU1BSX19fX19EQzQzOTUy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC43952&amp;Transmission_Id=202512141124PR_NEWS_USPR_____DC43952&amp;DateId=20251214"/>

11:24 ET
			
			
				DXCM CLASS ACTION ALERT:  Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Shareholders of Securities Fraud Class Action Lawsuit

德康医疗集体诉讼警报：Kessler Topaz Meltzer & Check, LLP 提醒德康医疗公司股东注意证券欺诈集体诉讼案